Revelation Biosciences, Inc.
REVB
$0.785
-$0.005-0.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.65% | 18.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.45% | -2.38% | |||
| Operating Income | -19.45% | 2.38% | |||
| Income Before Tax | -18.86% | 23.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.86% | 23.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.86% | 23.01% | |||
| EBIT | -19.45% | 2.38% | |||
| EBITDA | -19.53% | 2.39% | |||
| EPS Basic | 57.60% | 62.79% | |||
| Normalized Basic EPS | 57.60% | 62.79% | |||
| EPS Diluted | 57.60% | 62.94% | |||
| Normalized Diluted EPS | 57.60% | 62.79% | |||
| Average Basic Shares Outstanding | 180.32% | 106.87% | |||
| Average Diluted Shares Outstanding | 180.32% | 106.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||